Impact of Comorbidities and Drug Interactions in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors.

Purpose: Androgen receptor pathway inhibitors (ARPIs) are widely prescribed in metastatic castration-resistant prostate cancer (mCRPC). Real-world frequencies and potential impacts of comorbidities and concomitant medication (conmed) interactions with ARPIs are not well described.

Methods: Patients receiving ARPIs for mCRPC were identified from the electronic Prostate Cancer Australian Database (ePAD).

[Childhood trauma and adolescent game addiction: the mediating effects of self-control].

Objectives: To investigate the association between childhood trauma and game addiction in adolescents, as well as the mediating effect of self-control.

Methods: A cross-sectional study was conducted using cluster random sampling. The participants were 2 664 adolescents from a senior high school in Henan Province.

[Association between maternal job burnout and adolescent depression: the chain mediating effect of maternal depression and parenting style].

Objectives: To investigate the association between maternal job burnout and adolescent depression and the mediating effect of maternal depression and parenting style.

Methods: A cross-sectional study was conducted. The cluster random sampling method was used to select 2 572 adolescents from 7 middle schools in Shanghai, China, from April to May, 2021.

Vanishing bile duct syndrome associated with pazopanib after progression on pembrolizumab.

Pazopanib, a tyrosine kinase inhibitor, has been a standard first-line treatment for metastatic renal cell carcinoma (mRCC). Recent trials combining pazopanib with programmed cell death protein 1 (PD-1) inhibitors, including pembrolizumab, have shown excessive hepatotoxicity. We report a case of fatal hepatotoxicity from vanishing bile duct syndrome (VBDS) associated with pazopanib treatment, in a patient previously exposed to pembrolizumab.